ID   ZR75.1 A3
AC   CVCL_YX82
DR   cancercelllines; CVCL_YX82
DR   Wikidata; Q98136621
RX   PubMed=20386540;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 2594; CYP19A1.
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0588 ! ZR-75-1
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 12-03-20; Last updated: 05-10-23; Version: 7
//
RX   PubMed=20386540; DOI=10.1038/sj.bjc.6605641;
RA   Evans A.H., Pancholi S., Farmer I., Thornhill A., Evans D.B.,
RA   Johnston S.R.D., Dowsett M., Martin L.-A.;
RT   "EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in
RT   HER2/ER-positive breast cancer cells but functions synergistically
RT   with endocrine therapy.";
RL   Br. J. Cancer 102:1235-1243(2010).
//